Hepatitis B Surface Antigen - Quantitative Test

Hepatitis B surface antigen (HBsAg) is a protein found on the outer shell of the hepatitis B virus (HBV). Measuring its concentration in the blood, known as quantitative HBsAg (qHBsAg), provides valuable insights into how active the virus is inside the liver. Unlike a standard hepatitis B surface antigen test that simply reports positive or negative, the quantitative version gives an actual number, expressed in international units per milliliter (IU/mL). That number reflects the viral “footprint” inside liver cells, where HBV hides as covalently closed circular DNA (cccDNA) or integrates into the cell’s own genetic material.

This biomarker acts like a window into the virus’s activity level and the immune system’s control over it. In the immune-tolerant phase, often seen early in infection, qHBsAg levels are typically very high because the virus is replicating freely while the immune system remains quiet. As the immune system begins to recognize and fight the infection during the immune-clearance phase, qHBsAg levels start to fall. In the inactive carrier phase, where the infection is quiet and liver damage is minimal, levels are much lower, usually under 1000 IU/mL, and often below 100 IU/mL in certain HBV genotypes (such as genotypes B and C).

Because of this relationship, qHBsAg helps clinicians differentiate between phases of chronic hepatitis B and identify true inactive carriers: those at low risk for progression to cirrhosis or liver cancer. When qHBsAg is combined with HBV DNA testing (a direct measure of how much virus is in the blood), it can also predict long-term outcomes. Low qHBsAg and low HBV DNA together point to a stable, low-risk infection. In contrast, persistently high qHBsAg levels suggest ongoing viral activity and greater risk for hepatocellular carcinoma (HCC), the most common type of liver cancer associated with chronic hepatitis B.

Quantitative HBsAg is also a powerful tool for monitoring treatment response. In patients receiving pegylated interferon or nucleos(t)ide analogues, two main antiviral treatment classes, a rapid decline or low baseline qHBsAg predicts a higher chance of HBsAg loss, sometimes referred to as a functional cure. This information helps guide therapy decisions, such as determining whether treatment can be safely stopped, especially in HBeAg-negative patients.

That said, qHBsAg is not a replacement for HBV DNA testing; the two provide complementary information. qHBsAg reflects how much viral antigen is being made in the liver, while HBV DNA measures how much virus is circulating in the blood. Together, they give a more complete picture of infection activity and liver risk. Results should also be interpreted with context, as HBV genotype, disease phase, and even the type of treatment can influence the values.

Although qHBsAg testing has become more standardized in recent years, ongoing research is refining its role in managing patients on newer therapies and exploring how it might reduce the need for invasive liver biopsies. Overall, quantitative HBsAg provides clinicians and patients with a more nuanced, data-driven way to monitor chronic hepatitis B and guide long-term management toward remission or cure.